Literature DB >> 2114365

Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A.

A Fattom1, R Schneerson, S C Szu, W F Vann, J Shiloach, W W Karakawa, J B Robbins.   

Abstract

Epidemiological, serological and in vitro phagocytosis experiments provide evidence that the newly discovered type 5 and type 8 capsular polysaccharides (CPs) are both virulence factors and protective antigens for bacteremia caused by Staphylococcus aureus. Neither type 5 nor type 8 CP elicited serum antibodies when injected into mice. These two CPs were bound to Pseudomonas aeruginosa exotoxin A (ETA) to form conjugates by using the synthetic scheme devised for the CP (Vi) of Salmonella typhi and of pneumococcus type 12F (A. Fattom, W. F. Vann, S. C. Szu, A. Sutton, X. Li, D. Bryla, G. Schiffman, J. B. Robbins, and R. Schneerson, Infect. Immun. 56:2292-2298, 1988; S. C. Szu, A. L. Stone, J. D. Robbins, R. Schneerson, and J. B. Robbins, J. Exp. Med. 166:1510-1524, 1987). Both S. aureus CP-ETA conjugates elicited a rise in CP antibodies. As components of conjugates, both S. aureus CPs acquired T-cell-dependent properties, as shown by their ability to respond to carrier priming and to stimulate booster responses. The conjugate-induced antibodies facilitated type-specific opsonization of S. aureus by human polymorphonuclear leukocytes. The conjugates also induced ETA antibodies which neutralized the native toxin in vitro. Clinical studies of these two conjugates for active or passive immunization of patients at risk for S. aureus bacteremia are planned.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114365      PMCID: PMC258821          DOI: 10.1128/iai.58.7.2367-2374.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  47 in total

1.  Toxin inhibitors of protein synthesis: production, purification, and assay of Pseudomonas aeruginosa toxin A.

Authors:  B H Iglewski; J C Sadoff
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

2.  Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes.

Authors:  W W Karakawa; A Sutton; R Schneerson; A Karpas; W F Vann
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

3.  Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis.

Authors:  V L Yu; A Goetz; M Wagener; P B Smith; J D Rihs; J Hanchett; J J Zuravleff
Journal:  N Engl J Med       Date:  1986-07-10       Impact factor: 91.245

4.  Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.

Authors:  S C Szu; A L Stone; J D Robbins; R Schneerson; J B Robbins
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

5.  Reactivity of type-specific monoclonal antibodies with Staphylococcus aureus clinical isolates and purified capsular polysaccharide.

Authors:  M J Nelles; C A Niswander; W W Karakawa; W F Vann; R D Arbeit
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

6.  Staphylococcus aureus bacteremia. Current clinical patterns.

Authors:  C M Nolan; H N Beaty
Journal:  Am J Med       Date:  1976-04       Impact factor: 4.965

7.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

8.  A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.

Authors:  V K Chaudhary; C Queen; R P Junghans; T A Waldmann; D J FitzGerald; I Pastan
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

9.  Isolation of type 5 capsular polysaccharide from Staphylococcus aureus.

Authors:  J M Fournier; K Hannon; M Moreau; W W Karakawa; W F Vann
Journal:  Ann Inst Pasteur Microbiol       Date:  1987 Sep-Oct

10.  Effects of eliminating a disulfide bridge within domain II of Pseudomonas aeruginosa exotoxin A.

Authors:  I H Madshus; R J Collier
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.609

View more
  46 in total

Review 1.  Antistaphylococcal vaccines and immunoglobulins: current status and future prospects.

Authors:  Stan Deresinski
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis.

Authors:  I M Nilsson; J C Lee; T Bremell; C Rydén; A Tarkowski
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

3.  Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats.

Authors:  J C Lee; J S Park; S E Shepherd; V Carey; A Fattom
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

4.  Temperature-sensitive mutants ofStaphylococcus aureus: Isolation and preliminary characterization.

Authors:  D O Sordelli; M F Iglesias; M C Cerquetti; M Catalano; A M Hooke
Journal:  Curr Microbiol       Date:  1993-09       Impact factor: 2.188

5.  Adaptive Immunity Against Staphylococcus aureus.

Authors:  Hatice Karauzum; Sandip K Datta
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

6.  Effects of culture conditions on production of type 5 capsular polysaccharide by human and bovine Staphylococcus aureus strains.

Authors:  B Poutrel; F B Gilbert; M Lebrun
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

7.  The capsular polysaccharide of Staphylococcus aureus is attached to peptidoglycan by the LytR-CpsA-Psr (LCP) family of enzymes.

Authors:  Yvonne Gar-Yun Chan; Hwan Keun Kim; Olaf Schneewind; Dominique Missiakas
Journal:  J Biol Chem       Date:  2014-04-21       Impact factor: 5.157

8.  Phenotypic and genotypic characterization of nosocomial Staphylococcus aureus isolates from trauma patients.

Authors:  T Na'was; A Hawwari; E Hendrix; J Hebden; R Edelman; M Martin; W Campbell; R Naso; R Schwalbe; A I Fattom
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

9.  Vaccine assembly from surface proteins of Staphylococcus aureus.

Authors:  Yukiko K Stranger-Jones; Taeok Bae; Olaf Schneewind
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

10.  Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes.

Authors:  S Xu; R D Arbeit; J C Lee
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.